individual assignment CADD-Bioinformatics tools By: Wafda Rohhimi … Continue reading →

Bioinformatics tool By: Syahida Ishak … Continue reading →

Department of Computational Medicine and Bioinformatics The U-M Department of Computational Medicine and Bioinformatics (DCM&B) was launched in January 2012. Its purpose is to create novel informatics and computationally-based methods, tools, and algorithms to extend the capabilities and results of basic and clinical research. The department consists of the Bioinformatics Graduate Program, the Center for Computational Medicine and Bioinformatics (CCMB), the Bioinformatics Core, and the National Center for Integrative Biomedical Informatics (NCIBI). DCM&B is led by Dr. Brian Athey, the department chair. - View Core Faculty The Bioinformatics Graduate Program was established as an interdepartmental program in 1998 at the University of Michigan, and enrolled its first class in 2001. The Bioinformatics Graduate Program is led by co-directors Dr. Margit Burmeister, Professor of Psychiatry and Human Genetics and Dr. Daniel M. Burns Jr., Professor of Mathematics. The program maintains a graduate student body of approximately 45 Ph.D. and Master's students combined. The U-M Center for Computational Medicine and Bioinformatics (CCMB) is a campus-wide interdisciplinary academic center with over 100 affiliated faculty members. The faculty membership of CCMB has a strong representation from diverse fields such as mathematics, computer science, and statistics, and is complemented by faculty with biological and biomedical … Continue reading →

In 10% of human tumors there is a family history of hereditary disease associated with mutations in identified genes. The best examples are the cases of polyps in the large intestine associated with the APC gene and breast cancer associated with BRCA1 and BRCA2 genes. In the remaining 90% of cases are believed to have an increased risk of developing cancer in relation to genetic variants less powerful but more often, for example, doubles the risk of having a tumor that lacks this small change, called polymorphisms. In the last decade, hundreds of studies have been conducted looking for polymorphisms associated with a greater propensity to suffer some of the most frequent human tumors. These tests, called GWAS, have found a common problem: many times the tiny genetic change observed appears to have no activity or function to explain because it is associated with more cancer. Today, an article published in Cell Reports led by Manel Esteller, Director of Epigenetics and Cancer Biology, Bellvitge Biomedical Research Institute (IDIBELL) , ICREA researcher and Professor of Genetics at the University of Barcelona, solves part of this enigma . Research shows that in one in four human tumor exist genetic polymorphisms associated with … Continue reading →